---
aliases:
  - RA-APL
---
Retinoic acid, specifically **[[acute lymphoblastic leukemia]]-trans retinoic acid (ATRA)**, plays a crucial role in the treatment of Acute Promyelocytic [[Leukemia]] ([[acute promyelocytic leukemia]]). [[acute promyelocytic leukemia]] is characterized by the accumulation of immature white [[Blood]] cells (promyelocytes) due to the presence of the PML-RARA fusion [[gene]], which results from a specific chromosomal translocation. This fusion [[gene]] disrupts the normal maturation of white [[Blood]] cells, leading to the development of [[Leukemia]].

### Role of All-Trans Retinoic Acid (ATRA) in APL:

1. **Interactions**:
   - ATRA works by binding to the retinoic acid receptor alpha (RARÎ±) portion of the PML-RARA fusion protein, which is created by the t(15;17) translocation in [[acute promyelocytic leukemia]] cells.
   - This binding alters the function of the fusion protein, leading to the differentiation of the immature promyelocytes into mature white [[Blood]] cells. Essentially, ATRA reverses the maturation block that characterizes [[acute promyelocytic leukemia]], allowing the cells to differentiate and eventually die off normally.

2. **Combination with Other Therapies**:
   - ATRA is often used in combination with arsenic trioxide (ATO), which also targets the PML-RARA fusion protein, and in some cases, chemotherapy. The combination of ATRA and ATO has become the standard of care for [[acute promyelocytic leukemia]], especially in patients with lower-risk disease (based on white [[Blood]] cell count at diagnosis).
   - For higher-risk patients, ATRA is used alongside chemotherapy agents such as anthracyclines.

3. **Treatment Regimen**:
   - ATRA is typically administered orally and is part of an [[induction]] therapy phase aimed at achieving complete remission. Following [[induction]], consolidation therapy, which may include ATRA, ATO, and/or chemotherapy, is given to eliminate any remaining [[Leukemia]] cells.
   - Maintenance therapy with ATRA, sometimes in combination with low-dose chemotherapy, may be used to prevent relapse.

4. **Impact on Prognosis**:
   - The introduction of ATRA has dramatically improved the prognosis for [[acute promyelocytic leukemia]] patients. Before ATRA was used, [[acute promyelocytic leukemia]] was one of the most fatal forms of [[Leukemia]]. With ATRA-based regimens, cure rates now exceed 80-90%, and many patients achieve long-term remission.
   - Early initiation of ATRA therapy is critical because [[acute promyelocytic leukemia]] is associated with a high risk of bleeding complications, which can be life-threatening if not promptly addressed.

### Side Effects and Considerations:
- Common side effects of ATRA include headache, dry skin, and mild [[Liver]] dysfunction. 
- A significant side effect to watch for is **differentiation syndrome** (formerly called retinoic acid syndrome), a potentially severe condition that can occur during treatment. It is characterized by [[Fever]], weight gain, [[Respiratory]] distress, and fluid accumulation. Differentiation syndrome is managed with [[Corticosteroids]], and early recognition is vital to prevent serious complications.

In summary, ATRA has transformed [[acute promyelocytic leukemia]] from a highly fatal disease into one that is highly curable, making it a cornerstone of [[acute promyelocytic leukemia]] treatment.